On the morning of March 15, Recreation Guard (stock code: 833575) was officially listed on the North Stock Exchange. The company is a biomedical company with structure-based antigen design as its core technology. It is mainly engaged in the research, development and industrialization of recombinant protein vaccines. Its biomedical industry is a strategic emerging industry that the country focuses on encouraging development.

Vaccine products are characterized by knowledge-intensive, high technical content, high risk of research and development, and complex processes. Since its establishment in 2008, Kangle Guardian has continued to develop and industrialize innovative vaccines, and at the same time, it is also strengthening in-depth cooperation with companies in the global industry. In January 2019, Kangle Guardian and our company signed the ''Recombinant Fifteen-valent Human Papillomavirus Vaccine Industrialization Technology Development Contract'', and obtained clinical trial approval in March 2022. This is currently approved worldwide The highest-priced HPV vaccine for clinical trials is currently progressing smoothly.

Cervical cancer is the second largest malignant tumor in women, and human papillomavirus (HPV) vaccine is the most effective means to prevent cervical cancer. The continuous innovation and upgrading of the vaccine research and development is of great significance to the protection of public health.

After the successful listing of Kangle Guardian on the Beijing Stock Exchange, it will help it give full play to its resource advantages, strengthen its technological innovation, and open up broader prospects for advantageous cooperation among our enterprises. It is expected that Chengda Bio and Recreation Guardian will work together to win-win, continuously deepen the layout of cutting-edge vaccine technology, and accelerate the development and industrialization of innovative biological products.